BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

被引：0
作者：
Foster, S. A. [1 ]
Milev, S. [2 ]
Hoog, M. [3 ]
Mason, O. [1 ]
Sardesai, A. [4 ]
Hasan, A. [1 ]
Marrone, C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Evidera, San Francisco, CA USA
[3] Evidera, Bethesda, MD USA
[4] Evidera, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1313
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND40
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [31] Treatment with Galcanezumab in Patients with Episodic Migraine: Results from the OpenLabel Phase of the PERSIST Study
    Yu, Shengyuan
    Zhou, Jiying
    Zhuang, Junpeng
    Liu, Hui
    Qian, Chenxi
    NEUROLOGY, 2023, 100 (17)
  • [32] Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab among Patients with Episodic and Chronic Migraine
    Ruff, Dustin
    Ford, Janet
    Starling, Amaal
    Detke, Holland C.
    Nichols, Russell
    Port, Martha
    Aurora, Sheena K.
    NEUROLOGY, 2019, 92 (15)
  • [33] Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab Among Patients with Episodic and Chronic Migraine
    Ruff, D.
    Ford, J.
    Starling, A. J.
    Detke, H. C.
    Nichols, R.
    Port, M.
    Aurora, S. K.
    HEADACHE, 2019, 59 : 101 - 101
  • [34] SHIFT FROM CHRONIC TO EPISODIC MIGRAINE STATUS AND HIGH- TO LOW-FREQUENCY EPISODIC MIGRAINE STATUS AMONG PATIENTS WITH TREATMENT-RESISTANT MIGRAINE IN A PHASE 3 GALCANEZUMAB STUDY
    Day, Kathleen A.
    Rettiganti, Mallik
    Ferguson, Margaret B.
    Stroud, Chad E.
    Trewin, Benjamin P.
    Takeshima, Takao
    Kingston, William S.
    CEPHALALGIA, 2020, 40 : 75 - 75
  • [35] Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine
    Yang, Chun-Pai
    Lee, Chia-Fang
    Dell'Agnello, Grazia
    Hundemer, Hans-Peter
    Lipsius, Sarah
    Wang, Shuu-Jiun
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (10) : 1653 - 1666
  • [36] Sustained Reduction of Migraine Headache Days in Patients with Episodic Migraine During Months 4 to 6 of Treatment with Galcanezumab
    Tepper, Stewart J.
    Ruff, Dustin
    Wietecha, Linda
    NEUROLOGY, 2020, 94 (15)
  • [37] Sustained Reduction of Migraine Headache Days in Patients With Episodic Migraine During Months 4 to 6 of Treatment With Galcanezumab
    Ferrari, Michel D.
    Tepper, Stewart J.
    Ruff, Dustin
    Wietecha, Linda
    CEPHALALGIA, 2019, 39 : 217 - 217
  • [38] Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
    Pozo-Rosich, Patricia
    Samaan, Karen H.
    Schwedt, Todd J.
    Nicholson, Robert A.
    Rettiganti, Mallikarjuna
    Pearlman, Eric M.
    ADVANCES IN THERAPY, 2021, 38 (06) : 3154 - 3165
  • [39] BUDGET IMPACT OF INTRAVENOUS EPTINEZUMAB IN THE PREVENTION OF CHRONIC MIGRAINE PATIENTS IN UNITED ARAB EMIRATES
    Elattar, M.
    Zidan, T.
    Saeed, S.
    Elsisi, G.
    VALUE IN HEALTH, 2024, 27 (12)
  • [40] Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
    Patricia Pozo-Rosich
    Karen H. Samaan
    Todd J. Schwedt
    Robert A. Nicholson
    Mallikarjuna Rettiganti
    Eric M. Pearlman
    Advances in Therapy, 2021, 38 : 3154 - 3165
12345